Novel, biologically active substances from nature often provide excitement, stimulation, challenges, and opportunities for the scientific and medical communities. Experience and wisdom dictate investigation of their chemistry and pursuit of their chemical synthesis for more often than not, the rewards for both chemistry and medicine are great. The enediyne anticancer antibiotics are a rapidly emerging class of such compounds derived from bacterial sources. Combining unprecedented and highly unusual molecular architecture, phenomenal biological activities and fascinating modes of action, these DNA cleaving compounds burst onto the scene in the latter half of the 1980s when their structures became known, and they rapidly moved to center stage. Today the enediyne family includes the neocarzinostatin chromophore, the calicheamicins, the esperamicins, and the dynemicins, and soon the number of family members is certain to increase. These molecules elicited extensive research activities in chemical, biological, and biomedical circles and inspired the design of a number of novel molecular assemblies to probe and mimic their chemical and biological actions. A new body of synthetic technology and several novel synthetic strategies have already been devised to address the challenges posed by these molecules, and several new DNA cleaving agents have been designed and synthesized. This article summarizes the chemistry and biology of the enediynes and discusses mechanistic, synthetic, molecular design, and DNA cleavage aspects associated with the field.

No abstract

The rational design and biological actions of a new class of DNA-cleaving molecules with potent and selective anticancer activity are reported. These relatively simple enediyne-type compounds were designed from basic chemical principles to mimic the actions of the rather complex naturally occurring enediyne anticancer antibiotics, particularly dynemicin A. Equipped with locking and triggering devices, these compounds damage DNA in vitro and in vivo on activation by chemical or biological means. Their damaging effects are manifested in potent anticancer activity with remarkable selectivities. Their mechanism of action involves intracellular unlocking and triggering of a Bergman reaction, leading to highly reactive benzenoid diradicals that cause severe DNA damage. The results of these studies demonstrate the potential of these de novo designed molecules as biotechnology tools and anticancer agents.

No abstract